Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Henlius In-licenses Novel ESR1 Antagonist Therapy for Breast Cancer in $58 Million Deal

publication date: Jan 12, 2024

Shanghai Henlius Biotech acquired China rights to a novel clinical-stage breast cancer therapy developed by Sermonix Pharma of Columbus, Ohio. Henlius will have rights to develop, manufacture and commercialize lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in China. It made an upfront payment to Sermonix and will pay up to $58 million in milestones, plus royalties. Sermonix develops novel drugs that treat metastatic breast cancers harboring ESR1 mutations. Lasofoxifene is a novel endocrine therapy that has shown robust target engagement as an ESR1 antagonist for breast cancer. More details....

Stock Symbol: (HK: 2696)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital